Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate-cancer patients by Holcomb, Ilona N. et al.
1 
Genomic alterations indicate tumor origin and varied metastatic potential of  
disseminated cells from prostate-cancer patients 
Authors 
Ilona N. Holcomb1,6,7,8, Douglas I. Grove2,7,9,10, Martin Kinnunen3,6 , Cynthia L. Friedman1,6, Ian S. 
Gallaher3,6, Todd M. Morgan3,6, Cassandra L. Sather4,11,12, Jeffrey J. Delrow4,11, Peter S. Nel-
son1,6, Paul H. Lange3,6, William J. Ellis3,6, Lawrence D. True5,6, Janet M. Young1,13, Li 
Hsu2,7,9,10,14,15, Barbara J. Trask1,6,7,8,11,15,16,17, and Robert L. Vessella3,6,7,18 
 
1Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109; 
2Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 
98109; 3Department of Urology, University of Washington, Seattle, WA 98195; 4Genomics Re-
source, Fred Hutchinson Cancer Research Center, Seattle WA, 981099; 5Department of Pa-
thology, University of Washington, Seattle WA, 98195 
 
Running title: Genomic changes in disseminated cells from prostate cancer 
 
Key words: Disseminated tumor cells, disseminated cells, prostate cancer, array CGH, ge-
nomic alterations 
 
Acknowledgments: The authors gratefully acknowledge the support and technical expertise of 
members of the Trask, Vessella, and Nelson laboratories, especially Roger Coleman, Ilsa 
Coleman, Edward Arfman, Christine Wang, Bryce Lakely, and Mengchu Wu.  
                                                 
6Pacific Northwest Prostate Cancer SPORE CA97186 
7U.S. Department of Defense DAMD 17-03-2-0033 
8NIH/National Human Genome Research Institute Genome Training T32 HG00035 
9NCI P50-CA97186 
10National Institute on Aging RO1-AG14358 
11Fred Hutchinson Cancer Research Center Institutional Funds 
12NCI P30-CA15704-31 
13NIH RO1-DC004209 
14NIH RO1 CA098415 
15NIH RO1-CA95717 
16 NIC U24-CA80295 
17Request for reprints and correspondence should be addressed to  
Barbara J. Trask  
1100 Fairview Ave. N.  
Mail Stop C3-168 
PO Box 19024  
Seattle, WA 98109 
btrask@fhcrc.org  
18Request for reprints and correspondence may also be addressed to  
Robert L. Vessella  
Department of Urology, Box 356510 
UW Medical Center 
1959 NE Pacific St 
Seattle, WA  98195 
vesella@u.washington.edu 
2 
ABSTRACT 
Disseminated epithelial cells can be isolated from the bone marrow of a far greater frac-
tion of prostate-cancer patients than the fraction of patients who progress to metastatic disease. 
To provide a better understanding of these cells, we have characterized their genomic altera-
tions. We first present an array comparative genomic hybridization method capable of detecting 
genomic changes in the small number of disseminated cells (10-20) that can typically be ob-
tained from bone-marrow aspirates of prostate-cancer patients. We show multiple regions of 
copy-number change, including alterations common in prostate cancer, such as 8p loss, 8q gain, 
and gain encompassing the androgen-receptor gene on Xq, in the disseminated cell pools from 
11 metastatic patients. We found fewer and less striking genomic alterations in the 48 pools of 
disseminated cells from patients with organ-confined disease. However, we identify changes 
shared by these samples with their corresponding primary tumors and prostate-cancer altera-
tions reported in the literature, evidence that these cells, like those in advanced disease, are 
disseminated tumor cells (DTCs). We also demonstrate that DTCs from patients with advanced 
and localized disease share several abnormalities, including losses containing cell-adhesion 
genes and alterations reported to associate with progressive disease. These shared alterations 
might confer the capability to disseminate or establish secondary disease. Overall, the spectrum 
of genomic deviations is evidence for metastatic capacity in advanced-disease DTCs and varia-
tion in that capacity in DTCs from localized disease. Our analysis lays the foundation for eluci-
dation of the relationship between DTC genomic alterations and progressive prostate cancer. 
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INTRODUCTION 
 The metastatic potential of a tumor is presumably contained within cells that are able to 
escape and disseminate from the primary lesion. Consequently, the identification of cytokeratin-
positive cells (i.e., cells of epithelial origin) in the peripheral circulation and bone marrow of pa-
tients with clinically localized adenocarcinoma of the prostate has generated much interest. 
These cells are hypothesized to originate from the primary tumor and represent a very early 
stage in the metastatic process (1). The presence of these putative disseminated tumor cells 
(DTCs) in the bone marrow is particularly noteworthy, since bone metastases are a well known 
feature of lethal metastatic prostate cancer (2). It seems likely that these cells are the source of 
metastatic disease in those patients who develop secondary tumors years after resection of the 
primary tumor. Thus, DTCs have become a key target for risk-association studies and experi-
ments characterizing molecular features that underlie the phenotypic traits responsible for sur-
vival, dormancy, and ultimately proliferation in environments distinct from their origin.  
 There is a compelling need for improved ways to evaluate patients with clinically-
localized prostate cancer for their risk of developing metastasis. Currently, risk is estimated by 
the pathological features of the primary tumor (e.g., Gleason Score and tumor stage) and PSA 
levels in peripheral blood (3, 4). These predictive features are used to stratify patients into low- 
and high-risk groups. However, up to 50% of patients classified as high risk for progression do 
not develop metastasis, and ~10% of patients classified as low risk for progression subse-
quently develop secondary disease (5). Thus, the need to more accurately distinguish those 
men who would benefit from aggressive adjuvant treatment regimes from those who could be 
safely treated by active surveillance is a powerful motivation to improve upon the ability to pre-
dict outcome. 
 To date, some studies have found a positive correlation with the presence of DTCs and 
risk of relapse following primary therapies for localized prostate cancer (6-10), while others have 
not (11-16). Among the latter studies, Pfitzenmaier et al. (2007) found that 75% of pre-surgery 
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patients without clinical evidence of metastatic spread, and only 11% of normal controls, har-
bored disseminated epithelial cells in their bone marrow. This frequency far exceeds the ex-
pected frequency of biochemical recurrence or metastasis. These results strongly suggest that 
the mere presence of DTCs is not indicative of risk of disease progression. Why do so many 
patients possess DTCs, if escape from the primary tumor is a rate-limiting step in the metastatic 
process? Despite the low incidence in normal controls, it is possible that the disseminated cells 
are not actually tumor cells. Characterization of the molecular features of disseminated cells 
might resolve the question of their tumor origin and provide a better understanding of their rela-
tionship with disease progression.  
 Low-resolution and low-throughput methods such as fluorescence in situ hybridization 
(FISH) (17) or conventional comparative genomic hybridization (CGH) (18) have provided some 
evidence that DTCs from epithelial cancers possess genomic abnormalities. However, the mo-
lecular characterization of DTCs by high-resolution techniques has been hampered by the small 
number of DTCs obtainable: typically fewer than 50 epithelial cells from bone-marrow aspirates 
are available for analysis. To date, high-resolution genomic analysis was only possible by first 
generating cell lines from DTCs (19). 
 Given the proposed role that DTCs play in systemic disease and the paucity of genomic 
analyses of these cells, we have used array CGH to produce high-resolution genomic profiles of 
cells expressing epithelial markers isolated from the bone marrow of prostate-cancer patients. 
We categorize our samples by the status of the patients from which they were acquired. Thus, 
our samples of disseminated cells obtained from patients with organ-confined (localized) dis-
ease are designated as LocDCs. Our samples of disseminated cells from patients with metas-
tatic (advanced) disease are referred to as AdvDCs. Our study of genomic changes in LocDCs 
and AdvDCs lays the groundwork for a better understanding of the role these cells play in car-
cinogenesis.  
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MATERIALS AND METHODS 
Sample acquisition. All samples were collected from patients undergoing treatment at 
the University of Washington Medical Center or the VA Puget Sound Health Care System after 
informed consent was obtained. A total of 59 prostate-cancer patients (11 patients with ad-
vanced disease and 48 patients with localized disease), participated in this study. Supplemental 
Table 1 gives the Gleason grade and TNM stage for 55 of the patients and chemical castration 
status for all advanced patients. Clinical data on 4 localized patients was unavailable. The mean 
(SD) age of these patients was 60.2 (7.4) years. Our use of human samples for this study was 
approved by the Institutional Review Boards of the participating institutions.  
 Just prior to radical prostatectomy, bone-marrow aspirates were collected from the upper 
iliac crest of all patients with localized disease. Bone-marrow aspirates were collected from ad-
vanced patients prior to any treatment for four patients and during the course of treatment for 
seven patients. Pools of 10-20 epithelial cells were isolated and collected into 10 μl H20 based 
on expression of EpCAM (CD326; a pan-epithelial cell antigen) from the aspirates of each of 58 
patients and from three biological replicates from the aspirate of one metastatic patient, as de-
scribed previously (14). Twenty of the 59 samples (14 from localized- and 6 from advanced-
disease patients) were collected using 1:20 dilutions of both an anti-EpCAM(CD326) antibody 
conjugated with a fluorescein isothiocyanate isomer (Dako, Carpinteria, CA) and an anti-CD45 
antibody conjugated to R-phycoerythrin (Dako) to label normal hematopoietic cells. This dual 
detection system was used to exclude normal lymphocytes from disseminated-epithelial-cell 
pools and to collect samples of normal-cell samples. These samples were analyzed by array 
CGH and used to define thresholds of loss and gain in disseminated-cell arrays (see Supple-
mental Methods and Results) and in proof-of-principle tests (see Results). 
Prostate-tissue samples containing tumor were collected from the patients with localized 
disease following radical prostatectomy and were embedded in freezing media (Tissue-Tek 
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OCT Compound, Sakura Finetek, Torrance, CA) and stored in liquid nitrogen. For nine patients 
from whom LocDCs were collected, the entire prostate was histologically evaluated (see Sup-
plemental Table 1 for matched pairs). The area selected for molecular analysis was from the 
tumor, which was not multifocal in any of the cases. Tumor cells were isolated by laser-capture 
microdissection (LCM) from 5-μm thick tissue sections as described previously (20). Two to four 
thousand cells were collected from each patient and from the normal stroma of five patients. 
Pathologist (L.D.T.) review of all LCM images confirmed collection of tumor cells. Arrays of 
stromal-cell samples were used to define thresholds of copy-number change in arrays of pri-
mary tumor (see Supplemental Methods and Results).  
  
All other methods are described in Supplemental Methods and Results.  
 
RESULTS 
Array CGH can be made compatible with small numbers of cells. To analyze sam-
ples containing only 10-20 cells by array CGH, we first amplified the genomic DNA using a liga-
tion-mediated PCR method. This approach, which we term rare-cell genomic amplification 
(RCGA), was developed by Klein and coworkers to analyze the genome of a single cell by con-
ventional CGH (18). Our CGH platform was a bacterial artificial chromosome (BAC) array, which 
contains ~4200 BAC clones, each with a known location in the publicly available assembly of 
the human genome (Build 35), and provides a resolution of ~0.4 Mbp across the euchromatic 
portions of the genome (21). For all small-cell-number arrays, the reference is normal female 
genomic DNA amplified by RCGA from an amount of DNA roughly equivalent to the amount in 
the test sample.  
We conducted tests to establish that RCGA and array CGH when applied to small num-
bers of cells give (1) consistently low levels of experimental noise, (2) acceptable dynamic 
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range for detecting chromosomal alterations, and (3) reproducibility across replicates. First, we 
amplified nine samples each composed of 10-20 normal CD45-positive bone marrow-derived 
cells (from patients with localized prostate cancer) by RCGA and analyzed them by array CGH. 
We used these normal-cell array results to define thresholds for calling loss and gain (see Sup-
plementary Methods). Applying these thresholds back to the normal-cell arrays, we observed 
the expected X- and Y-chromosome shifts for all these comparisons of male test to female ref-
erence DNA. On average, only 1% (40/4096) and 0.6% (23/4096) of autosomal BACs were en-
compassed by segments designated as lost and gained, respectively. No site was called a de-
viation in more than two normal-cell arrays, and only four loci encompassing a total of 28 BACs 
were called deviant in two of the nine (~20%) normal-cell arrays. Thus, we report below only 
deviations detected in >20% of LocDC or AdvDC samples in order to minimize the risk of report-
ing false-positive deviant loci. 
 We next tested the ability of RCGA and array CGH to detect deviations in small numbers 
of cells of the LNCaP prostate-cancer cell line, which has well characterized genomic abnor-
malities (22). Four samples each composed of 10 or 20 cells collected by micropipetting, and 
one sample comprised of 200 ng of bulk genomic DNA purified from cells of the same passage, 
were independently amplified by RCGA for array CGH analysis. The analysis of bulk LNCaP 
DNA identified 13 sites of deviation, all previously reported for this cell line (22). Seven of the 13 
(54%) deviant loci observed in the bulk sample were identified in all of the samples of 10-20 
cells, and 11 of 13 (85%) were observed in at least one of the arrays from the 10- or 20-cell 
pools. The two deviations observed in the bulk sample but not in the small-cell-number samples 
each encompassed only two BACs. Thus, short deviations might be missed in arrays of DNA 
amplified from a small number of cells.  
 We found 8.5 additional deviant loci, on average, per array of 10-20 LNCaP cells. We 
selected five of these deviations to verify by FISH, using one of the BACs encompassed by 
each deviation as FISH probe. FISH demonstrated a heterogeneous mix of cells with and with-
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out the deviation of interest for three of the five copy-number alterations assessed (data not 
shown). Thus, random selection from a heterogeneous population contributes to the deviations 
detected by array CGH in small samples of LNCaP cells. 
We next demonstrated the reproducibility of our approach using three biological repli-
cates composed of 20 DTCs each collected from a single patient with metastatic prostate can-
cer. Each 20-cell sample was independently isolated from bone marrow, amplified, labeled, and 
analyzed by array CGH. Figure 1A shows the high correlation between the normalized log2-ratio 
values of each possible pair of replicates. Numerous sites of copy-number change spanning 
many Mbp of genomic material were identified for this patient’s samples. Figure 1B shows the 
considerable number of consistent deviant segments for the three replicates. Of the 3,077 BACs 
encompassed by alterations in one or more of these arrays, 72% (2219/3077) were identified in 
all three cell samples, and 88% (2716/3077) were deviant in two or more samples.  
 
The numerous genomic alterations in AdvDCs include those associated with pros-
tate cancer and disease progression. High-level amplifications as well as loss or gain of 
many segments encompassing several Mbp were detected in all 11 AdvDC samples. On aver-
age, each AdvDC array detected 13 gains and 14 losses. All chromosomes showed a deviation 
in at least one of the AdvDC samples. Figure 2 summarizes the deviations observed in the 
AdvDC samples. The list of copy-number changes observed in three or more samples (≥27%) is 
extensive (Supplemental Table 2).  
 The minimally overlapping regions (MORs) of copy-number change for deviations ob-
served in at least four samples (36%) are given in Table 1. This list of MORs includes many 
chromosomal locations reported in the literature as frequent alterations for primary or metastatic 
prostate tumors, including loss on 8p, 10q, 13q, and 16q, and gain on 8q and Xq. Our results 
help narrow in on the regions of interest for these prostate-cancer related alterations. We show 
five discrete MORs on 10q, three on 13q, three on 16q, and four on Xq.  
9 
 
Genomic alterations support the tumor origin of LocDCs. Based on the lack of clear 
associations between the mere detection of DTCs in men with clinically localized prostate can-
cer and subsequent relapse, an important question is if what we call DTCs are in fact tumor 
cells. To address this question, we compared the LocDC array results with the results from the 
primary tumor and AdvDC arrays. First, we found that the log2 ratios of the deviant autosomal 
segments for the LocDCs have a significantly lower dynamic range than those of the primary 
tumors and AdvDCs (Student’s t-test p < 0.05). The median log2 ratio of gained segments in 
LocDCs was 0.13 (SD = 0.07), in primary tumors 0.21 (SD = 0.11), and in AdvDCs 0.15 (SD = 
0.15). The median log2 ratio of segments classified as loss for LOCDCs was -0.15 (SD = 0.10), 
for primary tumors -0.17 (SD = 0.09), and for AdvDCs -0.17 (SD = 0.15). Second, we found 
fewer deviations, on average, in LocDCs (avg. = 14) than in primary tumors (avg. = 43) or 
AdvDCs (avg. = 27).  
We determined that normal-cell contamination is unlikely to be responsible for the dimin-
ished dynamic range in LocDC arrays. The normalized log2-ratio values for LocDCs collected 
using a marker (CD45) to exclude normal hematopoietic cells were not significantly different 
than those from LocDCs collected without this marker (p=0.1362). Moreover, AdvDCs were 
collected by the same methods as LocDCs, yet showed no evidence of normal-cell contamina-
tion.  
Despite the less striking amplitude and number of deviations in LocDCs, we provide evi-
dence that they are tumor cells. We exclude experimental noise as being responsible for the 
deviations observed in LocDCs. We compared LocDC array results to the normal-cell arrays 
(produced from the nine samples of 10-20 normal CD45+ cells collected and amplified in paral-
lel with the LocDC samples). The deviant segment values for gains and losses of autosomal 
material in the LocDC and normal-cell arrays were not significantly different (Student’s t-test p = 
0.16 and 0.09, respectively). However, the number of alterations and the amount of genomic 
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material altered were significantly greater in LocDC arrays than those found in the arrays of 10-
20 normal cells. LocDC samples showed an average of 14 deviations (3.5-fold more than nor-
mal cells, p = 0.005) and ~320 Mbp of altered genomic material (7.8-fold more than normal cells, 
p = 0.039).  
Seventeen loci showed copy-number deviation in >20% of LocDCs (Table 2, Figure 3). 
Thirteen of these loci are likely to be real chromosomal deviations because they have no over-
lap with deviant segments in normal-cell arrays. Losses involving 13q22 and 19q12 seen in 
>20% of the LocDCs encompass significantly more BACs than overlapping deviations regis-
tered in the normal-cell arrays (18 vs. 9, and 9 vs. 2 BACs respectively) and are thus also can-
didate tumor-related changes. We discount two deviations (gain in 4p16 and 11q13) as prob-
able experimental artifact, because they appeared in ~20% of normal-cell arrays.  
 A comparison of the genomic profiles of LocDC and primary tumors indicates several 
overlapping regions of deviation (Figure 3A and Table 2) supporting their common origin. Nine 
of the 15 (60%) sites of genomic change detected in >20% of the LocDC samples (excluding 
the two sites discounted as possible artifact) were also detected as deviant, in the same direc-
tion, in >20% of the primary tumor arrays. Moreover, 12 of the 15 loci showing change in >20% 
of the LocDC samples correspond to previously reported deviations in prostate cancer (Table 2, 
(23-28)), providing additional evidence that the LocDCs are prostate-tumor cells.  
Direct comparison of concordant sites in the nine matched samples of LocDCs and pri-
mary tumors provides additional evidence that LocDCs are tumor cells. A concordant deviation 
was defined as one in which >30% of BACs in one sample’s deviation were encompassed by 
the other sample’s deviation, and vice versa. There were a total of 29 concordant sites of devia-
tion across the nine sample pairs (Table 3), an average of 3.2 concordant loci per pair. For 24 of 
the concordant sites, >50% of BACs were shared. Only one pair lacked concordant alterations. 
Using simulated data sets, we found that three of the matched pairs have significantly more 
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concordant changes than the number expected if the deviant segments were randomly distrib-
uted across the two genomes.  
The degree of concordance we observe is unlikely to be affected by the different amplifi-
cation schemes used to amplify LocDCs (RCGA) and primary tumors (WGA2) (see Supplemen-
tal Methods and Results for detailed comparisons of RGCA and WGA2). In brief, arrays pro-
duced from LNCaP DNA amplified by these two methods showed significant concordance in 
their sites of genomic change (p<0.0001) and no significant difference in the dynamic range of 
the deviant segments (p=0.4820).  
 
Frequent LocDC alterations are often detected in AdvDCs but not vice versa. We 
compared the array-CGH profiles of LocDCs and AdvDCs to look for changes that might illumi-
nate the shared or divergent biology of these cell types. Ten (67%) of the 15 deviations ob-
served in >20% of the LocDC samples (excluding those discounted as artifacts) were also ob-
served in >20% of the AdvDC samples (Table 2). This set of loci includes loss at 8p23, one of 
the putative tumor suppressor containing regions on 8p (29), which was observed in 27% (3/11) 
of AdvDC samples and 23% (11/48) of LocDC samples. Two of the four most prevalent changes 
seen in the AdvDC samples were seen in >20% of the LocDC samples. Loss at 10q26 was ob-
served in 55% (6/11) of AdvDC samples and 25% (12/48) of LocDC samples. Loss at 16q21 
was also observed in 55% (5/11) of AdvDC samples and in 31% (15/48) of the LocDC samples.  
Given the remarkable degree of genomic change in AdvDCs and the more limited devia-
tions in LocDCs, it is not surprising that the majority of deviations that we observed in >20% of 
AdvDC samples were deviant in fewer than 20% of LocDC samples (Figure 3B and Supplemen-
tal Table 2). For example, losses that overlap with 8p12-21 and 8p22 were observed in four of 
the eleven (36%) AdvDC samples, five of the nine (56%) primary tumor samples, but only one 
of the 48 (2%) LocDC samples. Two deviations with considerable frequency differences was a 
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gain of most of 8q (36% of AdvDCs and 10% of LocDCs) and gain of 1q32 (45% of AdvDCs and 
8% of LocDCs).  
 
Regions of frequent chromosomal alteration in DTCs and primary tumors are en-
riched for genes of involved in specific biological processes. We sought to determine if the 
chromosomal regions altered in DTCs and primary tumors impact genes of particular biological 
processes, based on gene ontology (GO) enrichment analysis. We considered all regions al-
tered in >20% of the LocDC, AdvDC, or primary tumor samples (Supplemental Table 3), identi-
fied the genes corresponding to sites of loss or gain, and used hypergeometric tests (30) to de-
termine if any GO categories were enriched (at a significance level of p < 0.001) in those gene 
sets. The enriched categories are given in Supplemental Table 4 (losses) and Table 5 (gains). 
We also include a second p-value, the SimPValue, which is an indicator of those GO categories 
that might be enriched due to gene clustering. Thus, categories with a SimPValue > 0.05 should 
be considered with caution.  
The notable GO categories significantly enriched in alterations for >20% of the LocDC, 
AdvDC, or primary tumor samples with a SimPValue < 0.05 are as follows. Of the four catego-
ries enriched in the LocDC regions of gain, one was vitamin transport. This particular GO en-
richment included FOLR1, a gene whose transcript and protein product are increased in specific 
epithelial tumors and are positively associated with tumor stage and grade (31). DNA metabolic 
process and chromatin modification were two of the six categories enriched in primary tumor 
gains, and cell-cell signaling was one of the 12 categories enriched in primary tumors losses. 
Various immune related processes made up the six categories enriched in the AdvDC regions 
of gain. Only electron transport was an enriched category in AdvDC losses (SimPValue = 0.001). 
One of the electron transport genes in AdvDC regions of loss was the tumor suppressor WWOX 
(32).  
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 A few enriched gene categories with SimPValue > 0.05 represent biological processes 
that are sufficiently compelling to note here. Two categories related to adhesion (cell-cell adhe-
sion (SimPValue = 0.051) and homophilic cell adhesion (SimPValue = 0.054)) were enriched in 
LocDC regions of loss. Transcription, DNA packaging, chromatin assembly, and protein-DNA 
complex assembly were GO categories enriched in the primary tumor gains. Eight categories 
related to regulation of transcription, metabolic, cellular, and biological processes were enriched 
in AdvDC losses.  
  
DISCUSSION 
To the best of our knowledge, this study represents the highest resolution genome-wide 
analysis of changes performed directly on prostate-cancer DTCs. The genome analysis of a 
small number of cells was made possible by combining RCGA, a whole-genome amplification 
scheme developed by Klein et al. (18), and array profiling by CGH. The use of a spotted DNA 
array as a CGH platform detects loss and gain at a high resolution and provides a direct link to 
the sequence of the human genome, a considerable improvement over conventional methods. 
Our proof-of-principle studies show that it is possible to produce genomic profiles of a small 
number of cells that exhibit relatively low levels of experimental noise, highly concordant results 
between bulk DNA and samples of a small number of cells, and excellent reproducibility across 
biological replicates.  
 We demonstrate that LocDCs have real genomic deviations and are composed of tumor 
cells, even though the genomic deviations in the LocDC samples were generally fewer in num-
ber and showed lower dynamic range than those in primary tumors and AdvDCs. First, we see 
significantly more deviations in the LocDC arrays than in the arrays of a comparably small num-
ber of normal cells, arguing against experimental noise as the source of alterations in LocDCs. 
Second, 80% of the deviant sites detected in >20% of the LocDC samples were previously re-
ported in the literature as altered for prostate tumors. Third, we show significant concordance 
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between a third of the matched pairs of LocDCs and primary tumors and that 60% (9/15) of the 
deviations observed in >20% of the all the LocDC samples were identified in our primary tumor 
samples.  
AdvDCs are unmistakably tumor cells, given their numerous genomic alterations. More-
over, AdvDCs frequently possess deviations known to associate with a progressed disease 
state; deviations that were infrequently observed in LocDCs. A notable example is gain of 8q 
(36% of AdvDCs and 10% of LocDCs), an alteration associated with advanced disease and 
poor outcome in patients with organ-confined disease (23, 33, 34). Regions containing the me-
tastasis-suppressor genes MKK4 (17p12) and KAI1 (11p11.2) were each deleted in ~30% of 
AdvDC samples but very few of the LocDCs. One-third of our AdvDC samples and none of the 
LocDC samples had a high-level amplification of the region on chromosome X encompassing 
the androgen receptor gene, a well characterized alteration specific to advanced disease (35, 
36). Gain of 1q32 was one of the most common alterations found in AdvDCs (45%), uncommon 
in LocDCs (8%), and absent in our set of primary tumors. Notably, 50% of the metastatic tumors 
analyzed by array CGH in a parallel study also have a gain of 1q32 (Holcomb et al., in prepara-
tion)19, indicating that this region is likely to be associated with advanced disease. Will the small 
number of patients with LocDCs possessing metastases-associated alterations represent a sig-
nificant proportion of progressors? Long-term follow-up studies are underway to answer this 
question.  
 Changes that we frequently observed in both AdvDCs and LocDCs might reflect their 
common origin or shared state of dissemination. Arguing for the latter, both DTC types showed 
frequent losses in 8p23, 10q, 13q, and 16q, alterations that have been frequently identified in 
prostate cancer (33). Deviations found in both types of DTCs, but that were absent from our 
primary tumor samples might be alterations related to dissemination. These sites include losses 
                                                 
19 Holcomb IN, Grove DI, Young JM, Kim TS, Gifford D, Hsu L, Nelson PS, Vessella RL, Trask BJ. High-
resolution analysis of metastatic tumors from prostate cancer. Manuscript in preparation 2008.  
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in 10q25.1, 13q22.2-32.1, 13q32-34, and 16q21. Interestingly, the loss in 16q21 encompasses 
two members of the cadherin family of adhesion genes (CDH8 and CDH11). Disruption of the 
cadherin pathway is implicated in tumor invasiveness and disease progression for a number of 
carcinomas (37). Analysis of a much larger set of matched primary and DTC samples will be 
needed to confirm what alterations are in fact specifically associated with dissemination.  
 The reduced amplitude of the genomic changes in LocDCs compared to AdvDCs and 
primary tumors could have several explanations. Copy-number changes can be dampened in 
the array-CGH readout by normal-cell contamination, abnormal ploidy, and heterogeneity. As 
we have shown, normal-cell contamination of our DTC samples is unlikely. Extra ploidy is also 
unlikely to be a factor in the LocDCs, as it is well established that most early prostate cancers, 
from which the LocDCs are presumably disseminated, are approximately diploid (38).  
 Genomic heterogeneity of LocDCs, as is seen in prostate tumors (39), is likely to con-
tribute to a reduction in amplitude of LocDC alterations. Moreover, early dissemination might 
contribute additional heterogeneity to LocDCs relative to what might be found in the tumor itself. 
Inclusion of cells that migrated before acquiring multiple genome changes in the pool of LocDCs 
will dilute and reduce the overall number of detected alterations relative to the primary tumor at 
the time of resection, which we observe. Early dissemination of LocDCs might also explain their 
notably infrequent possession of 8p12-22 loss, the most common copy-number alteration re-
ported in prostate cancer (35). Loss in this region was seen in only one of our 48 LocDC sam-
ples, in contrast with 54% of our primary tumors and 55% of our AdvDC samples. 
 How do our LocDC findings fit the current models of metastasis? The two predominant 
models are that (1) rare, highly metastatic cells within the primary tumor give rise to metastases, 
or (2) particular tumors, not rare cells, are prone to metastasis. In either case, the implication is 
that cells leave the primary tumor in possession of the molecular alterations necessary for sec-
ondary growth and survival. However, it is hard to imagine that the cells that generate secon-
dary disease in patients many years after the removal of their primary tumor possess full metas-
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tatic potential (40). Theories of tumor-cell dormancy have been proposed recently (41-43) sug-
gesting that DTCs from primary tumors might represent a dormant population of cells that can, 
through selection and mutation over time, acquire key molecular changes that will permit metas-
tatic growth (41). Dormancy is supported by our GO analyses, which showed an enrichment of 
genes related to proliferation in sites of frequent alteration in our primary tumor and AdvDC 
samples, but not in our LocDCs, indicating that growth is not a prevailing theme in LocDC al-
terations. Thus, additional genomic hits would seem to be required, if LocDCs are to become 
overt metastases. 
 The high fraction of prostate cancer patients with localized disease in whom DTCs can 
be detected, and the relatively low level of genomic disorder shown here for such cells are per-
suasive evidence that LocDCs have not, in the majority of cases, reached full metastatic poten-
tial. If a subset of these cells can produce clinically significant metastases, then it seems likely, 
from the large number of studies showing gross chromosomal deviations in metastatic tumors, 
that these cells must eventually undergo additional genomic events. However, a subset of the 
genomic abnormalities that we identified in LocDCs may prove to be harbingers of progressive 
disease. Follow-up clinical studies of the patient population studied here along with additional 
molecular characterization of LocDCs could provide insight into the metastatic potential of DTCs.  
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TABLES 
Table 1. Locations of minimally overlapping regions (MORs) of loss (A) and gain (B) detected in 
at least four of the 11 AdvDC samples.  
A.        B. 
Chr. Start (bp)* End (bp)* 
Size 
(Mbp)
Loss† 
(%)  Chr. Start (bp) End (bp) 
Size 
(Mbp)
Gain† 
(%) 
4 8096400 9860900 1.76 36  1 161466500 164524500 3.06 45 
6 75016100 92151400 17.14 36  1 198600100 211134100 12.53 45 
6 108616100 119669000 11.05 36  2 44100 6608800 6.56 36 
6 159454900 161225200 1.77 36  2 26184700 27484700 1.30 45 
8 3899600 23478900 19.58 36  2 42391900 43774500 1.38 36 
10 7937400 11961000 4.02 36  2 49511100 75725900 26.21 36 
10 43603000 44182000 0.58 55  2 86778900 110050700 23.27 36 
10 78621100 103535200 24.91 36  3 4330000 11524200 7.19 36 
10 105726300 111829100 6.10 36  5 561600 4351700 3.79 36 
10 129427500 135165800 5.74 55  5 150300400 151093500 0.79 36 
11 12608600 13908400 1.30 36  5 179467100 180610700 1.14 36 
11 32183800 36906400 4.72 45  6 52696900 53331800 0.63 36 
11 107883700 127572100 19.69 36  8 57031700 99396100 42.36 36 
13 49029900 56820600 7.79 45  9 222300 4407700 4.19 36 
13 73284100 73672800 0.39 55  9 89644000 98144400 8.50 36 
13 80203300 93116600 12.91 55  9 111819300 112900900 1.08 45 
14 69266000 69440800 0.17 36  9 127428500 130252600 2.82 45 
15 53535600 61214300 7.68 45  16 75800 1753000 1.68 36 
16 53822000 54962800 1.14 36  17 73516500 78200000 4.68 36 
16 60811600 63807800 3.00 45  X 7483600 24032000 16.55 36 
16 70010000 84688200 14.68 36  X 66108300 67961300 1.85 45 
21 26441500 26798300 0.36 36  X 73682500 99853100 26.17 36 
     X 148896100 153772100 4.88 36 
 
Abbreviations: Chr, chromosome.  
*The start and end position are based on Build 35 of the human genome sequence assembly 
and base pair positions have been rounded to the nearest one hundredth. 
†The percentage of AdvDC samples that shows the MOR. 
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Table 2. Losses (A) and gains (B) observed in >20% of LocDC arrays and the percentage of 
primary-tumor and AdvDC samples showing an overlapping alteration. A range of percentages 
is given for most deviations, since not all BACs were encompassed by deviation in the same 
number of samples.  
A. 
Losses            
Chr. Band 
Size 
(Mb) Start (bp)* 
% of 
LocDC 
(n=48) 
% of P 
(n=9) 
% of 
AdvDC 
(n=11) Ref. # 
5 p15.32-p15.2 5.92 4443000 23 11 0-9 NA 
5 p14.3-p14.1 9.86 18961000 21-23 11 0 NA 
8 p23.3-p23.2 4.06 1 20-23 56 27-36 (23) 
10 q25.1 5.67 106120000 21 0 36 (24, 25) 
10 q26.2-q26.3 6.95 128253000 21-25 0-22 45-55 (23) 
12 q24.31-q24.33 6.31 123397000 29-35 33 9-18 NA 
13 q14.3-q22.2 22.86 52193000 21-31 11-22 36-55 (23) 
13 q22.2-q32.1 19.87 75147000 21-44 0 36-55 (23) 
13 q32.3-q34 14.02 99244000 21-23 0 27-36 (23) 
16 q12.1-q13.5 5.52 49358000 21-23 33 27-36 (25) 
16 q21 7.17 57328000 23-31 0-22 27-45 (23) 
19 q12-q13.11 4.23 33315000 29-35 56 27 (23) 
        
B. 
Gains                   
Chr. Band 
Size 
(Mb) Start (bp)* 
% of 
LocDC 
(n=48) 
% of P 
(n=9) 
% of 
AdvDC 
(n=11) Ref. # 
3 p22.1-p21.1 11.25 42513000 21-33 0-56 9-18 (26) 
3 q28-q29 5.21 193293000 21-27 0 18 (26, 27) 
4** p16.3-p16.2 3.36 1178100 29 0 0 NA 
9 q33.2-34.11 5.00 125337000 23 22-44 36-45 (28) 
11† q12.1-q13.5 18.96 56620000 23 11-77 18-27 (23) 
 
Abbreviations: Chr, chromosome; P, primary tumor; Ref #, reference reporting deviation.  
*The start position is based on Build 35 of the human genome sequence assembly and base 
pair positions have been rounded to the nearest one hundredth. 
** Observed in 22% (2/9) of the arrays performed on 20-cell pools of CD45-positive normal 
bone-marrow cells. 
† Observed in 60% of the arrays performed using LCM-collected normal cells. 
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Table 3. The number of deviations observed in each matching pair of LocDC and primary tumor 
samples. The sample pairs with a significant number of concordant deviations (p < 0.05) are in 
bold. The column "concordant" gives the number of deviations for which at least 30% of the en-
compassed BACs were deviant in both the primary tumor and LocDC sample.  
 
  Number of deviations 
Sample 
Pair LocDC 
Primary  
Tumor 
Con-
cordant p-value 
1 49 29 12 <0.0001 
2 16 9 1 0.23 
3 12 35 2 0.12 
4 30 73 9 0.0003 
5 2 86 1 0.23 
6 14 43 1 0.43 
7 15 18 0 1.00 
8 4 49 1 1.00 
9 8 40 2 0.03 
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FIGURE LEGENDS 
Figure 1  
Reproducibility of array CGH on RCGA-amplified samples from 10-20 cells. Three pools of 20 
AdvDCs were collected independently and amplified independently. Arrays for the three biologi-
cal replicates were run in parallel against the same female reference. A. Scatterplots of the 
normalized (abbreviated “norm.”) log2-ratio values from each possible pair of replicates. The 
Pearson’s correlation coefficient (r) for each pair is given. B. The top plot is a whole-genome 
profile of the normalized log2-ratios for one of the replicates. The normalized average log2 ratio 
for each BAC is plotted on the y-axis and the midpoint of the genomic position (Build 35) of each 
BAC on the array is plotted on the x-axis. The three bottom graphs are whole-genome plots of 
deviant segments for each of the three replicates. The log2-ratio value, as determined by CBS, 
of each segment exceeding chromosome-specific thresholds is plotted on the y-axis, and the 
genome position of the deviant segment, as defined by the encompassed BACs, is plotted on 
the x-axis. Chromosome numbers are indicated along the x-axis.  
 
Figure 2 
Frequency of deviations in AdvDCs (n = 11). The frequency of AdvDC samples with a deviation 
(y-axis) is plotted at the genomic position of the midpoint of each BAC encompassed by the de-
viation. Blue presents the frequency of gains, and red represents the frequency of losses.  
 
Figure 3 
Comparison of copy-number changes observed in LocDC samples, matching primary tumors 
and AdvDC samples. A. Percent of deviations observed across the genome in LocDCs (dots) 
overlaid on the frequencies for primary tumors (bars). B. Percent of deviations observed across 
the genome in LocDCs (dots) overlaid on the frequencies for AdvDCs (bars). Light blue and or-
ange dots in both A and B indicate the percentage of LocDC samples (n = 48) with observed 
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copy-number change encompassing each BAC on the array. Blue and red bars give the fre-
quency of copy-number change in the nine matching primary tumor samples (A) or in the 11 
AdvDC samples (B). Deviation frequencies of zero are not plotted. The x-axis is the midpoint of 
the genomic position of each BAC on the array, with chromosome numbers indicated. Note that 
copy-number loss of chromosome X and gain of chromosome Y represent the normal state for 
comparisons of male test and female reference genomic DNAs.  
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